Physician profile
Andrew Kronenberg
NPI 1518972355
$10,972.45
in general payments reported to CMS, 2019-2025
27 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $1,387 · 2021: $1,174 · 2022: $479 · 2023: $1,665 · 2024: $2,563 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,145.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,170.56 | 2019-2025 | Watchman Flx, Watchman Access System |
| Biotronik INC. | $1,440.28 | 2019-2024 | Biomonitor, Amvia Edge |
| E.R. Squibb & Sons, L.L.C. | $870.39 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $461.48 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $460.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $440.54 | 2019-2025 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.82 | 2019-2025 | Jardiance |
| Pfizer INC. | $408.06 | 2019-2025 | |
| Amgen INC. | $350.30 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $290.97 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $267.74 | 2019-2025 | Lifevest |
| Baxter Healthcare | $247.43 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $243.46 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Actelion Pharmaceuticals US, INC. | $167.91 | 2019 | |
| Medtronic, INC. | $152.64 | 2024 | Symplicity G3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.61 | 2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $111.83 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $61.91 | 2023-2024 | Optimizer, Optimizer |
| Celgene Corporation | $54.61 | 2022-2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $41.20 | 2024 | |
| Edwards Lifesciences Corporation | $40.10 | 2019-2024 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $39.22 | 2023-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $25.60 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $23.16 | 2025 | Attruby |
| Medtronic Vascular, INC. | $19.08 | 2020 | |
| Glaxosmithkline, LLC. | $16.45 | 2025 | Arexvy, Shingrix |
| Bardy Diagnostics, INC. | $2.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kronenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.